SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Thursday reported a loss of $101.1 million in its fourth quarter.

The San Diego-based company said it had a loss of $2.08 per share.

The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of $2.28 per share.

The biopharmaceutical company posted revenue of $1.7 million in the period.

Mirati shares have dropped 11% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $195.60, more than doubling in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRTX at https://www.zacks.com/ap/MRTX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News